IRIS
RICEVUTO, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.276
AS - Asia 5.147
EU - Europa 5.075
SA - Sud America 572
Continente sconosciuto - Info sul continente non disponibili 252
AF - Africa 73
OC - Oceania 11
Totale 20.406
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.134
SG - Singapore 2.146
CN - Cina 1.139
IE - Irlanda 1.081
RU - Federazione Russa 926
TR - Turchia 696
SE - Svezia 613
IT - Italia 578
DE - Germania 524
BR - Brasile 473
HK - Hong Kong 431
VN - Vietnam 397
UA - Ucraina 340
GB - Regno Unito 335
FR - Francia 267
FI - Finlandia 205
CA - Canada 77
IN - India 77
BD - Bangladesh 73
CZ - Repubblica Ceca 42
JP - Giappone 41
AR - Argentina 34
PL - Polonia 29
MX - Messico 27
BE - Belgio 24
NL - Olanda 24
IQ - Iraq 23
ES - Italia 19
ZA - Sudafrica 19
MA - Marocco 16
CO - Colombia 15
CL - Cile 13
ID - Indonesia 13
AT - Austria 12
KR - Corea 12
EC - Ecuador 11
SA - Arabia Saudita 11
UZ - Uzbekistan 10
AE - Emirati Arabi Uniti 9
AU - Australia 9
MY - Malesia 9
LT - Lituania 8
PK - Pakistan 8
BG - Bulgaria 7
DZ - Algeria 7
KE - Kenya 7
PY - Paraguay 7
RO - Romania 7
TH - Thailandia 7
VE - Venezuela 7
CR - Costa Rica 6
DM - Dominica 6
EU - Europa 6
PE - Perù 6
PT - Portogallo 6
TN - Tunisia 6
JO - Giordania 5
NP - Nepal 5
EE - Estonia 4
HN - Honduras 4
JM - Giamaica 4
PH - Filippine 4
AZ - Azerbaigian 3
BO - Bolivia 3
CG - Congo 3
DO - Repubblica Dominicana 3
HR - Croazia 3
LU - Lussemburgo 3
MK - Macedonia 3
PA - Panama 3
PR - Porto Rico 3
PS - Palestinian Territory 3
RS - Serbia 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
TW - Taiwan 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
DK - Danimarca 2
ET - Etiopia 2
IL - Israele 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LY - Libia 2
MD - Moldavia 2
TJ - Tagikistan 2
TL - Timor Orientale 2
UY - Uruguay 2
BH - Bahrain 1
BW - Botswana 1
CI - Costa d'Avorio 1
EG - Egitto 1
GA - Gabon 1
GF - Guiana Francese 1
GH - Ghana 1
GM - Gambi 1
Totale 20.143
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.309
Chandler 1.216
Singapore 1.211
Dublin 1.081
Dallas 832
San Jose 825
Ashburn 530
Hong Kong 425
Santa Clara 414
Boardman 410
Izmir 327
Council Bluffs 280
Nanjing 236
The Dalles 198
Wilmington 194
San Mateo 191
New York 170
Lawrence 168
Princeton 168
Beijing 166
Ann Arbor 164
Moscow 158
Lauterbourg 114
Ho Chi Minh City 113
Hanoi 107
Milan 100
Los Angeles 89
Nanchang 87
Woodbridge 75
Munich 64
Seattle 64
Bremen 61
São Paulo 61
Shenyang 56
Tianjin 55
Des Moines 49
Helsinki 48
Hebei 44
L'aquila 43
Verona 43
Brno 40
Rome 38
Kunming 37
Tokyo 37
Columbus 35
Hefei 35
Changsha 31
Frankfurt am Main 30
Jiaxing 29
Sant'egidio Alla Vibrata 27
Mountain View 26
Warsaw 25
Brussels 24
London 24
Orem 24
Brooklyn 23
Shanghai 23
Dong Ket 22
Hangzhou 22
Jinan 22
Philadelphia 22
Norwalk 21
Toronto 21
Buffalo 19
Dearborn 19
Guangzhou 19
Montreal 19
San Francisco 19
Zhengzhou 19
Chennai 18
Denver 18
L’Aquila 17
Pune 17
Chicago 16
Atlanta 15
Auburn Hills 15
Pescara 14
Boston 13
Da Nang 13
Falkenstein 13
Phoenix 13
Amsterdam 12
Lanzhou 12
Ningbo 12
Changchun 11
Falls Church 11
Haiphong 11
Johannesburg 11
Rio de Janeiro 11
Turku 11
Monza 10
Nuremberg 10
Curitiba 9
New Delhi 9
Poplar 9
Stockholm 9
Tashkent 9
Ankara 8
Assago 8
Belo Horizonte 8
Totale 13.071
Salva come PNG Salva come JPEG
Nome #
Pyrroloquinoline Quinone (PQQ) Attenuates Hydrogen Peroxide-Induced Injury Through the Enhancement of Mitochondrial Function in Human Trabecular Meshwork Cells 429
The supportive care task force at the University of L'Aquila: 2-years experience 213
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? 199
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 185
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines 178
Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro 175
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. 171
Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. 169
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study 169
Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer 168
Antiproliferative and pro-apoptotic effects of 5-azacytidine in prostate carcinoma cells in vitro involve the recovering of PTEN-mediated Akt activity control and androgen sensitivity 164
P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer 162
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer 158
Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A 155
Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases 153
New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting 153
CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models 149
Oncology together for L'Aquila: early resumption of integrated oncological activities after the earthquake 149
Multidisciplinary palliation for unresectable recurrent rectal cancer: Hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study 148
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families 145
Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer 145
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. 144
Pain evaluation and management: a survey of Italian radiotherapists 143
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 143
Effects of Chemotherapy in Patients with Concomitant Aortic Aneurysm and Malignant Disease 143
A gene expression signature from bone metastases as predictor of clinical outcome in breast cancer patients 141
Mutazioni della p53 in campioni selezionati di adenocarcinoma del colon dell’Italia Centrale 140
p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumors 140
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, Fir-B/FOx, according to seconde-line treatment and KRAS genotype 140
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models 139
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study 138
Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: A retrospective study 138
Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study 137
Trifluoroibuprofen inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in Vivo Tumor Growth in Aggressive Prostate Cancer Models. 135
New mutations and protein variants of NBSI are identified in cancer cell lines 135
Recurrent Metastatic Pulmonary Synovial Sarcoma during Pregnancy: A Case Report and Literature Review 133
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer 133
Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer 132
Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells 132
Gabapentin in the treatment of severe sweating experienced by advanced cancer patients 131
Symptoms in advanced cancer: The influence of sex, age, Karnofsky Performance Status and PaP score. 130
Meccanismo d’azione e farmacologia di nuovi composti organometallici nel trattamento del carcinoma del colon-retto. 130
Oxaliplatin (l-OHP) association with paclitaxel (PTX) or docetaxel (DTX) in NSCLC cell lines: Schedule-dependent activity based on p53/microtubule associated protein 4 (MAP4) interaction 130
Poker association of weekly alternating 5-fluorouracil, irinotecan,bevacizumab and oxaliplatin (FIrB/FOx) in first line treatment of metastatic colorectal cancer: a phase II study 129
An association of epirubicin, etoposide and cisplatin in gastric cancer: a phase II study 128
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis 128
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 127
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). 127
Assessment and treatment of symptoms among italian medical oncologists 126
Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line 126
Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs 126
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 126
Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen 126
Novel P53 mutations detected by FAMA in colorectal cancers 125
Prognostic relevance of PIK3CA mutations in breast cancer patients treated with primary dose-dense epirubicin/cyclophosphamide -> dose-dense docetaxel 125
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 125
A KRAS and dual concomitant PI3KCA mutations in a metastatic colorectal cancer patient with aggressive and resistant disease 124
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases 124
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer. families 122
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 122
NEW MUTATIONS AND PROTEIC VARIANTS OF NBS1 ARE IDENTIFIED IN CANCER CELL LINES 120
Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy 120
In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human cancer cells 120
Prognostic relevance of KRAS genotype and the prevalent C.35 G > a mutation in metastatic colorectal cancer (MCRC) patients fitting for intensive FIr-B/FOx triplet chemotherapy plus bevacizumab 119
A six-gene signature predicting breast cancer lung metastasis 119
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 119
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: An experience of multidisciplinary management in clinical practice 119
Choice of chemotherapy schedules in elderly patients (> 75 years) with metastatic colorectal cancer (mcrc) according to comorbidity 118
Multidisciplinary management of hepatocellular carcinoma in clinical practice 117
Short-term weekly neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer 115
Can analysis of the molecular status of the p53 gene contribute to improving the therapeutic strategy for breast carcinoma? 114
Familiarity and heredity of tumors in function of an early surgical therapeutic approach 113
Plasma proteomic profiling in hereditary breast cancer reveals a BRCA1-specific signature: Diagnostic and functional implications 113
ABERRANT HYPERMETHYLATION OF THE P16 GENE IN SPORADIC GASTRIC CANCER 112
Significato prognostico e predittivo delle alterazioni genetiche nel carcinoma gastrico 112
Role of estrogen receptor alpha in aggressiveness and osteoclastogenic potential of human breast carcinoma cells. 112
Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease 112
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient WithKRASMutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy 112
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study 112
Medical emergencies in oncology: hypercalcemia. II. Diagnosisand therapy 111
Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts 111
Role of immunoscintigraphy in clinical assessment of gastrointestinal tumors 111
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. 110
Home care for cancer patients after an earthquake: the experience of the "L'Aquila per la Vita" Home Care Unit 110
In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma 109
Valutazioni seriate del peptide natriuretico cerebrale sono predittive di cardiotossicità da antracicline in pazienti sottoposti a chemioterapia non ad alte dosi 109
Oxaliplatin:preclinical in vitro studies 109
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation 109
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. 109
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro 108
Intraperitoneal chemotherapy [LA CHEMIOTERAPIA INTRAPERITONEALE] 108
Carcinoma della pelvi renale e dell'uretere 108
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models 107
Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. 107
Awareness of disease severity in Italian breast cancer patients submitted to mastectomy or conservative surgery 107
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program 107
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevaizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52 106
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study 106
Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments 106
Timed-flat infusion of 5-fluorouracil associated with docetaxel as first-line treatment of patients with metastatic breast cancer 105
Totale 13.351
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.675
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.675
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.043 0 88 276 73 32 18 12 55 66 21 76 326
2022/20233.321 233 205 61 358 346 378 5 212 1.375 13 78 57
2023/2024717 116 44 33 103 50 178 16 63 0 28 27 59
2024/20253.197 97 73 308 134 439 268 469 286 678 83 199 163
2025/20266.313 310 635 553 714 553 496 1.148 214 494 656 405 135
2026/2027340 146 194 0 0 0 0 0 0 0 0 0 0
Totale 20.406